Guldstoev Pharma IVS

CVR number: 38548514
Bakkegårds Alle 4, 1804 Frederiksberg C
Guldstoev-Phama@guldstoev.dk
tel: 60889143
Guldstoev.com

Credit rating

Company information

Official name
Guldstoev Pharma IVS
Established
2017
Company form
Entrepreneurial limited company
Industry
  • Expand more icon21Manufacture of basic pharmaceutical products and pharmaceutical preparations

About Guldstoev Pharma IVS

Guldstoev Pharma IVS (CVR number: 38548514) is a company from FREDERIKSBERG. The company recorded a gross profit of 0 kDKK in 2018. The operating profit was 0 kDKK, while net earnings were 0 kDKK. The profitability of the company measured by Return on Assets (ROA) was 0 %, which can be considered poor and Return on Equity (ROE) was 0 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 0 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Guldstoev Pharma IVS's liquidity measured by quick ratio was 0 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.

Financial information

See financials

Gross profit (kDKK)

EBIT (kDKK)

Profitability

Solidity

Key figures (kDKK)

See financials
20172018
Volume
Net sales
Gross profit
EBIT
Net earnings
Shareholders equity total
Balance sheet total (assets)
Net debt
Profitability
EBIT-%
ROA
ROE
ROI
Economic value added (EVA)
Solvency
Equity ratio
Gearing
Relative net indebtedness %
Liquidity
Quick ratio
Current ratio
Cash and cash equivalents
Capital use efficiency
Trade debtors turnover (days)
Net working capital %
Credit risk
Credit ratingCC

Variable visualization

Companies in the same industry

Build time: 2024-10-21T13:51:26.353Z

Try the full version of our system for free
Bankruptcy risk visualization example

... and more!

No registration needed.